Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
Cronos Group's Capital Expenditure for the
three
months ended in Mar. 2024 was $-1.99 Mil. Its Revenue for the
three
months ended in Mar. 2024 was $25.29 Mil.
Hence, Cronos Group's Capex-to-Revenue for the
three
months ended in Mar. 2024 was 0.08.
Cronos Group Capex-to-Revenue Historical Data
The historical data trend for Cronos Group's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cronos Group's Capex-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cronos Group's Capex-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cronos Group's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where Cronos Group's Capex-to-Revenue falls into.
Cronos Group Capex-to-Revenue Calculation
Cronos Group's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cronos Group (NAS:CRON) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
Cronos Group Capex-to-Revenue Related Terms
Thank you for viewing the detailed overview of Cronos Group's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S. the company has an option to acquire 10.5% of U.S. multistate operator PharmaCann upon easing of federal prohibition.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRON has been successfully added to your 